SCA3 — ATXN3 (Ataxin-3)

SCA3 — ATXN3 (Ataxin-3)

Overview

Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD), is the most common dominant ataxia worldwide. The disease is caused by a CAG trinucleotide repeat expansion in the ATXN3 gene, which encodes the protein ataxin-3. This autosomal dominant disorder leads to progressive neurodegeneration primarily affecting the cerebellum, brainstem, and spinal cord, resulting in ataxia, dysarthria, ophthalmoplegia, and pyramidal signs.

SCA3 — ATXN3 (Ataxin-3)

Overview

Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD), is the most common dominant ataxia worldwide. The disease is caused by a CAG trinucleotide repeat expansion in the ATXN3 gene, which encodes the protein ataxin-3. This autosomal dominant disorder leads to progressive neurodegeneration primarily affecting the cerebellum, brainstem, and spinal cord, resulting in ataxia, dysarthria, ophthalmoplegia, and pyramidal signs.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">SCA3 / MJD</th></tr>
<tr><td><b>Gene Symbol</b></td><td>ATXN3</td></tr>
<tr><td><b>Full Name</b></td><td>Ataxin-3</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>14q32.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[6312](https://www.ncbi.nlm.nih.gov/gene/6312)</td></tr>
<tr><td><b>OMIM</b></td><td>[607047](https://www.omim.org/entry/607047)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9UHD8](https://www.uniprot.org/uniprotkb/Q9UHD8/entry)</td></tr>
<tr><td><b>Inheritance</b></td><td>Autosomal Dominant</td></tr>
<tr><td><b>Repeat Type</b></td><td>CAG (Polyglutamine)</td></tr>
<tr><td><b>Normal Repeat</b></td><td>12-44</td></tr>
<tr><td><b>Pathogenic Repeat</b></td><td>51-86</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">41 edges</a></td>
</tr>
</table>
</div>

Normal Function of Ataxin-3

Protein Structure

Ataxin-3 is a 361-amino acid protein encoded by the ATXN3 gene located on chromosome 14q32.1. The protein contains:

• N-terminal Josephin domain (JD): A catalytic domain with deubiquitinating enzyme (DUB) activity
• C-terminal polyglutamine (polyQ) tract: The pathogenic expansion occurs in this region
• Multiple VCP/p97 binding motifs (VBM): Involved in protein quality control
• Nuclear localization signals (NLS): Regulates subcellular trafficking

Deubiquitinase Activity

The Josephin domain functions as a deubiquitinating enzyme (DUB) that hydrolyzes ubiquitin chains, particularly those linked through Lys63 and Lys48. This activity is crucial for:

• Protein quality control: Removing ubiquitin from misfolded proteins for degradation
• Transcriptional regulation: Modulating histone ubiquitination
• Stress response: Processing ubiquitin conjugates during cellular stress

Normal Cellular Functions

In its normal state, ataxin-3 participates in several cellular processes:

Expression Pattern

Ataxin-3 is ubiquitously expressed with high levels in:

• Cerebellar Purkinje cells
• Brainstem neurons
• Spinal cord motor neurons
• Peripheral nervous system
• Heart, liver, and skeletal muscle

Disease Mechanism

Pathogenic Repeat Expansion

The CAG repeat expansion in ATXN3 results in an abnormally long polyglutamine (polyQ) tract in the ataxin-3 protein. The number of CAG repeats correlates with:

• Age of onset: More repeats → earlier onset
• Disease severity: Longer repeats → more severe phenotype
• Anticipation: Paternal transmission often leads to earlier onset in offspring

Gain-of-Function Toxicity

The expanded polyQ tract triggers pathogenesis through multiple mechanisms:

Protein Misfolding and Aggregation

The expanded polyQ sequence causes conformation changes in ataxin-3, leading to:

• Misfolding into beta-sheet rich structures
• Oligomerization into toxic species
• Formation of large aggregtes
• Sequestration of essential cellular proteins

Transcriptional Dysregulation

ATXN3 expansions disrupt normal transcriptional programs by:

• Sequestering transcription factors in aggregates
• Altering histone acetylation/deacetylation balance
• Dysregulating brain-derived neurotrophic factor ([BDNF](/genes/bdnf)) expression
• Affecting mitochondrial biogenesis genes

Mitochondrial Dysfunction

SCA3 neurons exhibit profound mitochondrial abnormalities:

• Reduced complex I and IV activity
• Decreased ATP production
• Increased reactive oxygen species ([ROS](/mechanisms/oxidative-stress))
• Impaired calcium buffering
• Damaged mitochondrial dynamics (fission/fusion)

Autophagy Impairment

The autophagy-lysosome pathway is compromised in SCA3:

• Reduced autophagic flux
• Impaired mitophagy
• Accumulation of damaged organelles
• Failure to clear mutant protein aggregates

Calcium Dysregulation

Neuronal calcium homeostasis is disrupted:

• Enhanced calcium release from ER stores
• Mitochondrial calcium overload
• Dysregulated calcium-dependent proteases
• Altered synaptic plasticity

Neuroinflammation

A chronic inflammatory response develops:

• Activated microglia in affected brain regions
• Elevated pro-inflammatory cytokines
• Complement system activation
• Blood-brain barrier disruption

Neuropathology

The characteristic neuropathological features of SCA3 include:

Clinical Features

Core Symptoms

| Symptom | Description | Frequency |
|---------|-------------|-----------|
| Ataxia | Progressive cerebellar gait and limb ataxia | Universal |
| Dysarthria | Scanning, explosive speech | >90% |
| Ophthalmoplegia | Horizontal gaze palsy, nystagmus | >80% |
| Pyramidal signs | Hyperreflexia, spasticity | 60-80% |
| Bulbar signs | Dysphagia, dysphonia | 50-70% |
| Peripheral neuropathy | Distal weakness, sensory loss | 40-60% |

Disease Subtypes

Three clinical phenotypes are recognized:

Progression

• Duration: 15-25 years from onset to death
• Wheelchair: Typically required 10-15 years after onset
• Cause of death: Respiratory complications, aspiration pneumonia

Genetics

Inheritance Pattern

• Autosomal dominant: One mutant allele is sufficient
• Anticipation: Earlier onset in successive generations (especially paternal)
• Penetrance: Near complete by age 70

Genetic Modifiers

Several genetic factors modify disease severity:

• CAG repeat length: Primary determinant of age of onset
• Hsp70 polymorphisms: Affect protein aggregation
• Autophagy gene variants: Modify clearance of mutant protein
• Mitochondrial haplogroups: Influence energy metabolism

Animal Models

Mouse Models

• Transgenic mice: Express human ATXN3 with expanded CAG repeats
• Knock-in mice: Murine ATXN3 with expanded repeats
• Conditional models: Inducible expression systems

Key Findings from Models

• Aggregate formation precedes behavioral deficits
• Mitochondrial dysfunction occurs early
• Autophagy modulation alters disease progression
• Gene silencing extends survival

Therapeutic Approaches

Gene Silencing

RNA interference (RNAi) and antisense oligonucleotides (ASOs) targeting ATXN3 have shown promise in preclinical models:

• AAV-delivered shRNA reduces mutant protein
• ASOs decrease ATXN3 expression
• Allele-specific silencing for heterozygous targeting

Pharmacological Approaches

| Approach | Target | Status |
|----------|--------|--------|
| DUB modulators | Ataxin-3 activity | Preclinical |
| Autophagy inducers | Protein clearance | Preclinical |
| Mitochondrial protectants | Bioenergetics | Preclinical |
| Antioxidants | ROS | Clinical trials |
| Calcium stabilizers | Ca2+ dysregulation | Preclinical |

Gene Therapy

• AAV-mediated delivery of therapeutic genes
• CRISPR-based approaches for repeat contraction
• Gene replacement strategies

Symptomatic Treatments

• Physical therapy for ataxia
• Speech therapy for dysarthria
• Botulinum toxin for spasticity
• Assistive devices for mobility

Biomarkers

Fluid Biomarkers

• Neurofilament light chain (NfL): Elevated in serum/CSF
• Tau protein: Altered phosphorylation patterns
• YKL-40: Marker of neuroinflammation

Imaging Biomarkers

• MRI: Cerebellar and brainstem atrophy
• PET: Hypometabolism in affected regions
• Diffusion tensor imaging: White matter damage

Animal Model Discoveries

Key insights from model systems:

Cross-Linking to Related Topics

Neurodegeneration Mechanisms

• [Polyglutamine Diseases](/diseases/polyglutamine-diseases) — Category of inherited ataxias
• [Proteostasis Failure](/mechanisms/proteostasis-failure) — Protein quality control breakdown
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy metabolism impairment
• [Autophagy impairment in neurodegeneration](/mechanisms/autophagy-neurodegeneration)

Related Genes

• [ATXN1](/genes/atxn1) — Spinocerebellar ataxia type 1
• [ATXN2](/genes/atxn2) — Spinocerebellar ataxia type 2 / ALS
• [ATXN7](/genes/atxn7) — Spinocerebellar ataxia type 7

Related Diseases

• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia) — Disease category
• [Machado-Joseph Disease](/diseases/machado-joseph-disease) — Alternative name

Research Directions

Current Clinical Trials

• Antisense oligonucleotide trials
• Gene therapy trials
• Biomarker natural history studies

Emerging Areas

• CRISPR-based gene editing
• Protein aggregation inhibitors
• Neuroregeneration approaches
• Biomarker-driven clinical trials

Key Publications

See Also

• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
• [Friedreich Ataxia](/diseases/friedreich-ataxia)
• [Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia)
• [Neurodegeneration](/diseases/neurodegeneration)
• [Polyglutamine Expansion Disorders](/diseases/polyglutamine-diseases)

External Links

• [NCBI Gene: ATXN3](https://www.ncbi.nlm.nih.gov/gene/6312)
• [UniProt: ATXN3](https://www.uniprot.org/uniprotkb/Q9UHD8/entry)
• [OMIM: 607047](https://www.omim.org/entry/607047)
• [GeneCards: ATXN3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ATXN3)
• [NIH - NINDS SCA3 Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Spinocerebellar-Ataxia-Type-3-Information-Page)

References

Pathway Diagram

Key molecular relationships involving sca3 from the SciDEX knowledge graph:

Pathway Diagram

The following diagram shows the key molecular relationships involving SCA3 — ATXN3 (Ataxin-3) discovered through SciDEX knowledge graph analysis: